Navigation Links
New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
Date:2/8/2012

IPSWICH, Mass. and LA JOLLA, Calif., Feb. 7, 2012 /PRNewswire/ -- New England Biolabs, Inc. (NEB) and Synthetic Genomics, Inc. (SGI) jointly announce that they have entered into a licensing agreement whereby NEB will introduce a master mix based on Gibson Assembly™, a revolutionary technology developed by Dr. Daniel Gibson and his colleagues at the J. Craig Venter Institute (JCVI) as part of a program sponsored by SGI. The financial details of this agreement were not disclosed.

(Logo: http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b )

Gibson Assembly enables the rapid assembly of multiple DNA fragments using a one-step, isothermal approach.  Since its introduction to the life science community in 2009, Gibson Assembly has become a mainstay in the laboratories of many synthetic biologists and is catching on in the wider life science community due to its ease-of-use, robustness and flexibility.

"New England Biolabs is delighted to work with SGI to introduce Gibson Assembly to our customers.  As a leader in the discovery and development of cloning tools and technologies, NEB has embraced this approach for building DNA constructs, and believes that it will open new opportunities for the manipulation of complex DNAs," states Richard J. Roberts, Ph.D., Chief Scientific Officer, NEB.

"The Gibson Assembly method is a powerful tool that we believe will enable synthetic biology researchers to make rapid advances leading to new discoveries and products," said J. Craig Venter, Ph.D., Founder and CEO, SGI.  "SGI is pleased to work with industry leader NEB in commercializing this product."

The Gibson Assembly Master Mix includes protocols for primer design, and can be used for assembly of multiple DNA fragments, including linearized vector and insert. For more information about the Gibson Assembly Master Mix, visit www.neb.com/gibsonassembly

About New England Biolabs
Established in the mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company, headquartered in Ipswich, MA and has extensive worldwide distribution through a network of exclusive distributors, agents and six subsidiaries located in Canada, China, France, Germany, Japan and the UK. For more information about New England Biolabs visit www.neb.com


About Synthetic Genomics
SGI, a privately held company founded in 2005, is dedicated to developing and commercializing genomic-driven solutions to address global energy and environment challenges. Advances in synthetic genomics present limitless applications in a variety of product areas, including: energy, chemicals and pharmaceuticals. The company's main research and business programs are currently focused on the following major bioenergy areas: designing advanced biofuels with superior properties compared to ethanol and biodiesel; harnessing photosynthetic organisms to produce value added products directly from sunlight and carbon dioxide; developing new biological solutions to increase production and/or recovery rates of subsurface hydrocarbons and developing high-yielding, more disease resistant and economic feedstocks. For more information go to www.syntheticgenomics.com

Gibson Assembly is a trademark of Synthetic Genomics, Inc.

 


'/>"/>
SOURCE New England Biolabs
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
2. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
3. SwitchGear Genomics and New England Biolabs Develop New Multiplex Reporter Assay System
4. New England Research Institutes (NERI) Announces Additional $45M NIH Grant to Support the Pediatric Heart Network
5. New England Biolabs and Rubicon Genomics Enter into Distribution Agreement for Single Cell Amplification Products
6. Biotech Group Warns Proposed Medicare Cuts Could Hurt Critical Sector of New England Economy
7. Agreement Between SomaLogic and New England Biolabs Enables the Use of SOMAmer Technology for the Optimization of Multiple PCR Products
8. Comprendia and New England Biolabs Connect Epigenetics Scientists with New Social Media Application
9. New England Biolabs Opens New Subsidiary Office in France
10. TEI Biosciences Wins SBANE 2011 New England Innovation Award
11. TEI Biosciences Chairman, President and CEO Yiannis Monovoukas Named Ernst & Young Entrepreneur Of The Year® 2011 New England Award Semifinalist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... NEW YORK , March 24, 2017 ... Composite ended the trading session at 5,817.69, down 0.07%; ... finish at 20,656.58; and the S&P 500 closed at ... session as 4 sectors closed in green, 4 sectors ... the day. This Friday, Stock-Callers.com has initiated reports coverage ...
(Date:3/23/2017)... Research and Markets has announced the ... to their offering. ... The Global Market for Bioproducts Should Reach ... a CAGR of 8.9%, This research report ... seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and ...
(Date:3/23/2017)... CT (PRWEB) , ... March 23, 2017 , ... ... LLC, was recently selected by the Connecticut Technology Council (CTC) as a 2017 ... at CTC’s thirteenth annual Women of Innovation Awards Dinner. , The dinner recognizes ...
(Date:3/23/2017)... 2017 In today,s pre-market research, ... the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate ... SYN), and Regulus Therapeutics Inc. (NASDAQ: RGLS ... Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn ... at: ...
Breaking Biology Technology:
(Date:3/2/2017)... , March 2, 2017 Summary ... to better understand Merck KGaA and its partnering interests ... https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals and ... the partnering activity of one of the world,s leading ... are prepared upon purchase to ensure inclusion of the ...
(Date:2/28/2017)... Germany , February 28, 2017 News ... ... Amsterdam from 14 to 16 March, Materna ... destination, and show how seamless travel is a real benefit for ... has added biometrics to their passenger touch point solutions to take ...
(Date:2/22/2017)... , Feb. 22, 2017 With the ... ABI Research identifies four technologies that innovative and ... secure significant share in the changing competitive landscape: ... passive authentication.   "Companies can no ... to security," says Dimitrios Pavlakis , Industry ...
Breaking Biology News(10 mins):